Protagenic therapeutics exec Garo Armen buys $944 in stock

On August 19, 2026, Garo H. Armen, the Executive Chair and Principal Officer of Protagenic Therapeutics, Inc. (NASDAQ:PTIX), acquired 2,700 shares of the company's common stock. The total cost of this transaction amounted to $944, with Armen purchasing the shares at a price of $0.35 per share. As a result of this insider purchase, Mr. Armen's direct beneficial ownership of Protagenic Therapeutics common stock increased to 36,899 shares.

The recent stock market performance of PTIX has been quite concerning. Over the past year, PTIX shares have experienced a significant decline of 85%, currently trading at $0.40 per share. This share price represents a far cry from its 52-week high of $6.20. Despite its modest market capitalization of $630,000, the company's shares appear to be somewhat overvalued according to InvestingPro analysis, suggesting that investors may want to tread with caution.

In terms of upcoming events, PTIX is scheduled to report its earnings tomorrow, August 21. Investors should keep a close eye on the company's earnings report as it may provide valuable insights into the company's financial health and future prospects. For those interested in Protagenic Therapeutics, InvestingPro offers 7 additional exclusive tips for PTIX subscribers, which could be worth exploring for further information.